Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin+Meropenem vs Amikacin+Meropenem for MDR Gram-Negative Bacteria
NCT07694700Phase 4Active, not recruiting
- Sponsor
- Beni Suef University
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
A Phase 4 trial of colistin, amikacin in Gram-negative bacterial infection, sponsored by Beni Suef University. Started Dec 2025; status: active, not recruiting.
02
Drugs
colistinamikacin
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT07694700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694700.